Abstract
Background
Atrial fibrillation (AF) is treated by heart rate (HR) control. However, the optimal HR target in AF patients with heart failure (HF) remains unclear. To evaluate the clinical implication of the resting HR in AF patients with HF accompanied by preserved, mid-range, or reduced ejection fraction (HFpEF, HFmrEF, or HFrEF, respectively).
Methods
Echocardiographic data from June 2016 to April 2020 in a prospective, multicenter, observational registry from 11,104 patients were analyzed. The follow-up duration was 2.2 years. The main outcome was composite of death and hospitalization. We categorized patients according to the HF type and resting HR: ≤ 60 bpm, 61–80 bpm, 81–110 bpm, and >110 bpm.
Results
A total of 1,421 patients were enrolled in the study: 582 in the HFpEF group, 506 in the HFmrEF group, and 333 in the HFrEF group. The patients had a mean age of 69 ± 11 years and consisted of 872 (61.4%) men. Primary endpoint rates among HFpEF patients with 60 < HR ≤ 110 bpm were lower than those with HR ≤ 60 bpm (61–80 bpm group: hazard ratio, 0.66; 95% CI, 0.46–0.94; p = 0.021; 81–110 bpm group: hazard ratio, 0.60; 95% CI, 0.40–0.90; p = 0.013). Especially, HFpEF patients with HR 81–110 bpm had a lower incidence of hospitalization caused by HF aggravation than those with other HR strata (HR ≤ 80bpm strata or HR >110 bpm strata). In HFmrEF and HFrEF patients, the survival rates did not differ significantly among patients in the three groups with HR ≤ 110 bpm. Moreover, the event rates increased significantly in HFmrEF patients with HR >110 bpm (hazard ratio, 1.91; 95% CI, 1.16-3.14, p = 0.011).
Conclusion
In patients with AF and HFpEF, the resting HR has U-shaped associations with the overall primary endpoint. A lower or higher resting HR is associated with increased cardiovascular outcomes, especially in patients with HFpEF and AF.
Keywords: heart failure, atrial fibrillation, rate control, heart failure preserved ejection fraction, U shape curve
Introduction
Heart failure (HF) is commonly accompanied by atrial fibrillation (AF) irrespective of the concomitant left ventricular ejection fraction (LVEF) (1). Rhythm control in patients with HF and AF is associated with lower mortality and morbidity (2); however, the optimal heart rate (HR) target in AF patients with HF remains unclear. According to the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic HF, the estimated HR is 60–110 bpm (3). In the RACE II trial, lenient rate control (>110 bpm) was as effective as strict rate control in persistent AF patients (4). However, this study did not include patients with HF (the average LVEF was approximately 52%), and the incidence of a previous hospitalization for HF was only about 10%.
In HF patients without AF, the target for an appropriate HR has not been specified. In patients with an HR ≥70 bpm taking the maximally tolerated dose of beta-blockers, ivabradine was recommended (5). In contrast to sinus rhythm, slower HRs are not associated with survival benefits in AF (6). The irregular rhythm of AF also has detrimental effects on systolic and diastolic heart function independent of HR (7, 8). These factors may explain why titration using a beta-blocker fails to reduce mortality or morbidity in AF, unlike in sinus rhythm.
HF with preserved ejection fraction is as common as the syndrome with reduced LVEF (9); however, the target HR in patients with HF with preserved ejection fraction (HFpEF) and AF is not clear. In this prospective, multicenter, observational study (in 12 tertiary hospitals in Korea), we investigated the clinical characteristics and implications of the resting HR in AF patients with HF, for the three subtypes of HF defined by the LVEF.
Methods
Study Protocol
In a prospective observational registry (COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF] registry), 11,104 patients with non-valvular AF were consecutively enrolled between June 2016 and April 2020 from 12 tertiary centers in Korea (10). All patients were >18 years old. After enrollment, each patient was followed up every 6 months, either through the outpatient clinic or by telephone contact. This study was conducted in accordance with the Declaration of Helsinki and the relevant guidelines and regulations. The study protocol was approved by the Research Ethics Committee of all 12 tertiary centers including Ewha Womans University Mokdong Hospital (No. 216-02-056), and all patients provided their written informed consent prior to enrollment. This study was approved by the ethics committee of each center, and the study is registered at www.ClinicalTrials.gov (NCT 02786095).
Among the 11,104 participants enrolled in CODE-AF, we excluded 2,418 patients for missing data on HR (n = 582) and missing echocardiography records (n = 1,836). Among available AF patients with available data, patients without a history of HF (n = 7,140) or with a permanent pacemaker (n = 125) were also excluded (Figure 1).
Figure 1.
Flowchart of the study population enrollment. CODE-AF, COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation.
Definitions Used
The recent guidelines classify patients with HF in three categories: HF with preserved ejection fraction (HFpEF), defined by an LVEF ≥50%, HF with reduced ejection fraction (HFrEF) if the LVEF is <40%, and HF with mid-range ejection fraction (HFmrEF) if the LVEF is 40–49% (11). Considering the echocardiogram results and history of heart failure at the time of AF enrollment, the patients were diagnosed with HF. As suggested in the recent guidelines, we classified 1,421 patients with HF history in this study into HFpEF, HFmrEF, and HFrEF.
Baseline Covariates
We collected data on the clinical characteristics, medical history, comorbidities, blood pressure, medications, therapies, and interventions. Systolic and diastolic blood pressure and CHA2DS2-VASc score were included as continuous variables in the Cox regression models. Echocardiographic variables such as left atrial size, left atrial volume index, LVEF, and E/e' were collected.
In addition to other baseline variables, we recorded the stable HR before the deterioration and HR measured by electrocardiogram at discharge from the hospital or outpatient visits at the cardiology department. In paroxysmal AF patients, the heart rate was checked using EKG documented an atrial fibrillation rhythm. The HR was categorized into four strata and analyzed by a Cox regression model, the event rates, and hazard ratio: ≤ 60, 61–80, 81–110, and >110 bpm.
Outcomes
The primary outcome of this study was a composite of all-cause mortality and hospitalizations. A subgroup analysis of the primary outcome was also performed. The secondary outcomes of this study were composite clinical events including stroke, systemic embolism, major bleeding, myocardial infarction, and arrhythmic events (syncope, sustained ventricular tachycardia, and cardiac arrest). A stroke was defined as the sudden onset of a focal deficit consistent with an occlusion of a major cerebral artery (documented by imaging). Systemic embolisms were defined as an acute vascular occlusion of an extremity or organ as documented by imaging. Major bleeding was defined as a reduction in the hemoglobin level by at least 20 g/L, a transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ. Syncope was defined as a transient loss of consciousness that may have been caused by an arrhythmia. Sustained ventricular tachycardia was defined as hemodynamic compromised ventricular tachycardia lasting more than 30 s or requiring electrical termination. Cardiac arrest was defined as circulatory arrest requiring resuscitation and hospitalization (6). All-cause mortality and major adverse outcomes described above were checked by patient interviews and medical records during follow-up.
Statistical Analysis
Continuous variables are presented as the mean ± SD, whereas categorical variables are presented as counts and percentages. Comparisons of the variables across the groups were performed using Student's t test or a one-way ANOVA combined with a Bonferroni post hoc analysis for continuous variables and Chi-square (χ2) or Fisher's exact test for categorical variables, as appropriate. The primary analysis for the primary endpoint consisted of a comparison among the HFpEF, HFmrEF, and HFrEF groups for the time to the first occurrence of the composite primary outcome as assessed through Kaplan–Meier curves and by performing log-rank tests among the HR strata. Cox proportional hazards models were used to calculate the test hazard ratios in the HFpEF, HFmrEF, and HFrEF subgroups. The covariates used in all adjusted Cox models were clinical characteristics, medical history, comorbidity, blood pressure, medication, therapy, and intervention. We first constructed a baseline Cox model that included variables mentioned above. A penalized spline term for parity was used upon further examination of the data. We evaluated the model for proportional hazards assumptions, influential observations, and nonlinearity of continuous variables. The final model was fitted using the smoothHR package of R software (12) that estimates log hazard ratios and corresponding confidence intervals for nonlinear continuous variables. Statistical analyses were performed using the SPSS version 22.0 software package (IBM SPSS, NY, USA) and R version 3.6.2 smoothHR software package. A p < 0.05 was considered to indicate statistical significance.
Results
Baseline Characteristics
A total of 1,421 patients were enrolled in the study: 582 in the HFpEF group, 506 in the HFmrEF group, and 333 in the HFrEF group (Table 1 and Figure 1). The baseline characteristics of the study population are listed in Table 1. The patients had a mean age of 69 ± 11 years and consisted of 872 (61.4%) men. The mean CHA2DS2-VASc score was 3.4 ± 1.7, and 34% patients had persistent AF. The distribution of patients with HFpEF, HFmrEF, and HFrEF according to the resting HR is shown in Figure 2. The percentage of women (54%), valvular disease (15%), PeAF (38%) and prevalence of hypertension (75%) in the HFpEF group were higher than those in the HFmrEF and HFrEF groups. Valvular disease distribution based on ejection fraction is shown in Supplementary Material. However, there were more patients with a history of myocardial infarction (10%) and implantable cardioverter defibrillator insertion (12%) in the HFrEF group than in the HFpEF and HFmrEF groups.
Table 1.
Baseline characteristics based on the ejection fraction.
|
HFpEF (N = 582) |
HFmrEF (N = 506) |
HFrEF (N = 333) |
P value | |
|---|---|---|---|---|
| Age, years | 71 ± 10 | 68 ± 11 | 67 ± 11 | <0.001 |
| Male | 270 (46) | 361 (71) | 241 (72) | <0.001 |
| Persistent AF, n (%) | 217 (38) | 173 (34) | 97 (29) | 0.019 |
| CHA2DS2 VASc | 3.7 ± 1.6 | 3.1 ± 1.8 | 3.4 ± 1.8 | <0.001 |
| Follow up duration, days | ||||
| Median | 894 | 778 | 689 | 0.005 |
| Interquartile range | 351-1183 | 356-1112 | 267-1099 | |
| SBP, mmHg | 123 ± 16 | 118 ± 17 | 118 ± 17 | <0.001 |
| DBP, mmHg | 74 ± 13 | 74 ± 13 | 74 ± 14 | 0.788 |
| Medical history, n (%) | ||||
| Hypertension | 437 (75) | 325 (64) | 211 (63) | <0.001 |
| Diabetes mellitus | 153 (26) | 138 (27) | 113 (34) | 0.038 |
| Myocardial infarct | 11 (2) | 45 (9) | 33 (10) | <0.001 |
| Valvular disease | 86 (15) | 46 (9) | 25 (8) | 0.001 |
| Valvular surgery | 1 (0) | 0 (0) | 1 (0) | 0.508 |
| ICD | 13 (2) | 9 (2) | 40 (12) | <0.001 |
| Chronic kidney disease | 85 (15) | 75 (15) | 49 (15) | 0.995 |
| Smoker | 134 (23) | 148 (29) | 124 (37) | <0.001 |
| Rate-control medications in use no. (%) | ||||
| None | 209 (36) | 144 (28) | 97 (29) | 0.016 |
| Beta-blocker alone | 251 (43) | 3188 (37) | 122 (37) | 0.064 |
| Verapamil or diltiazem alone | 65 (11) | 82 (16) | 51 (15) | 0.040 |
| Digoxin alone | 8 (1) | 16 (3) | 6 (2) | 0.112 |
| Beta-blocker and CCB | 35 (6) | 51 (10) | 42 (13) | 0.002 |
| Beta-blocker and digoxin | 7 (1) | 15 (3) | 11 (3) | 0.062 |
| Digoxin and CCB | 7 (1) | 5 (1) | 1 (0) | 0.378 |
| Beta-blocker, digoxin, CCB | 0 | 5 (1) | 3 (1) | 0.061 |
| Other medications in use at baseline | ||||
| Warfarin | 118 (20) | 74 (15) | 63 (19) | 0.046 |
| NOAC | 362 (62) | 335 (66) | 222 (67) | 0.265 |
| ARB or ACEi | 310 (53) | 264 (52) | 232 (70) | <0.001 |
| Statin | 224 (38) | 194 (38) | 122 (37) | 0.841 |
| Antiplatelet | 95 (16) | 83 (16) | 64 (19) | 0.421 |
| Diuretics | 70 (12) | 35 (7) | 23 (7) | 0.002 |
| Echocardiographic variables | ||||
| Left atrial size, long axis, mm | 49 ± 8 | 46 ± 8 | 48 ± 9 | 0.029 |
| Left atrial volume index, ml/m2 | 58 ± 26 | 56 ± 28 | 62 ± 28 | 0.035 |
| LV ejection fraction, % | 61 ± 7 | 45 ± 3 | 31 ± 6 | <0.001 |
| E/e' | 15 ± 7 | 13 ± 6 | 16 ± 9 | <0.001 |
HFpEF, Heart failure preserved ejection fraction; HFrEF, Heart failure reduced ejection fraction; bpm, beat per minute; AF, atrial fibrillation; SBP, systolic blood pressure; DBP, diastolic blood pressure; ICD, implantable cardioverter-defibrillator; LV, left ventricle; CCB, calcium channel blocker (verapamil or diltiazem); NOAC, novel oral anticoagulants; ARB, angiotensin-receptor blockers; ACEi, angiotensin-converting-enzyme inhibitors.
Figure 2.
Heart rate distribution in HFpEF, HFmrEF and HFrEF. HFpEF, heart failure with preserved ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFrEF, heart failure with reduced ejection fraction.
Outcomes Related to the EF
The median follow-up was 2.2 (0.9–3.1) years. The primary endpoint occurred in 219 (17.4% per person-year) patients with HFpEF, 197 (19.2% per person-year) patients with HFmrEF, and 145 (22.9% per person-year) patients with HFrEF. The primary endpoint did not differ significantly among the groups. However, the secondary endpoint events were significantly more frequent in the HFmrEF (45; 4.4% per person-year) and HFrEF (28; 4.4% per person-year) groups than in the HFpEF group (17; 1.3% per person-year, p < 0.001) (Tables 2, 3).
Primary Outcomes Related to the HR
A total of 561 patients (19.2% per person-year) reached the primary outcome. Kaplan–Meier curves for the primary outcome are shown in Figure 3. In a multivariable cox regression analysis using baseline data corrected for age, sex, weight, AF type, CHA2DS2 VASc score, HR, systolic blood pressure, diastolic blood pressure, medical history, and medication in use, the survival rates among HFpEF patients with 60 < HR ≤ 110 bpm were lower than those with HR ≤ 60 bpm (61–80 bpm group: hazard ratio, 0.66; 95% CI, 0.46–0.94; p = 0.021; 81–110 bpm group: hazard ratio, 0.60; 95% CI, 0.40–0.90; p = 0.013) (Table 2). In HFmrEF and HFrEF patients, the survival rates did not differ significantly among patients in the three groups with HR ≤ 110 bpm. Moreover, the event rates increased significantly in HFmrEF patients with HR >110 bpm (hazard ratio, 1.91; 95% CI, 1.16–3.14, p = 0.011). Especially, HFpEF patients with HR 61–110 bpm had a lower incidence of hospitalization caused by HF aggravation than those with other HR strata (HR ≤ 60 bpm strata or HR >110 bpm strata) (In HR strata 61–80; hazard ratio, 0.70; 95% CI, 0.51–0.97; p = 0.030, In HR strata 81–110 hazard ratio, 0.58; 95% CI, 0.39–0.85; p=0.005) (Table 2). Moreover, HFmrEF patients with HR >110 bpm had significantly higher rate of hospitalization caused by HF (hazard ratio, 1.99; 95% CI, 1.18–3.36; p = 0.010).
Figure 3.
Kaplan–Meier curves. The primary endpoint according to the heart rate in patients with HFpEF, HFmrEF, and HFrEF is shown. HFpEF, heart failure with preserved ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFrEF, heart failure with reduced ejection fraction.
Table 2.
Cox regression analyses of the effect of the heart rate on the primary endpoint.
| HR strata, beats per min | No. of events | Hazard ratio (95% CI) | P value | |
|---|---|---|---|---|
| Composite primary endpoint | ||||
| In HFpEF | ≤ 60 bpm | 42 | Reference | |
| (n = 219, 17.4%/person-year) | 61–80 bpm | 118 | 0.66 (0.46–0.94) | 0.021 |
| 81–110 bpm | 52 | 0.60 (0.40–0.90) | 0.013 | |
| >110 bpm | 7 | 0.97 (0.44–2.11) | 0.944 | |
| In HFmrEF | ≤ 60 bpm | 31 | Reference | |
| (n = 197, 19.2%/person-year) | 61–80 bpm | 79 | 0.71 (0.47–1.08) | 0.106 |
| 81–110 bpm | 56 | 0.89 (0.57–1.37) | 0.587 | |
| >110 bpm | 31 | 1.91 (1.16–3.14) | 0.011 | |
| In HFrEF | ≤ 60 bpm | 19 | Reference | |
| (n = 145, 22.9%/person-year) | 61–80 bpm | 67 | 0.70 (0.42–1.19) | 0.188 |
| 81–110 bpm | 36 | 0.61 (0.34–1.10) | 0.099 | |
| >110 bpm | 23 | 0.93 (0.49–1.77) | 0.827 | |
| Individual components | ||||
| death | ||||
| HFpEF | ≤ 60 bpm | 2 | Reference | |
| (n = 15, 1.2%/person-year) | 61–80 bpm | 7 | – | |
| 81–110 bpm | 5 | – | - | |
| >110 bpm | 1 | – | - | |
| In HFmrEF: | ≤ 60 bpm | 1 | Reference | |
| (n = 7, 0.7%/person-year) | 61–80 bpm | 3 | – | |
| 81–110 bpm | 3 | – | ||
| >110 bpm | 0 | – | ||
| HFrEF: | ≤ 60 bpm | 0 | Reference | |
| (n = 9, 1.4%/person-year) | 61–80 bpm | 4 | – | |
| 81–110 bpm | 2 | – | ||
| >110 bpm | 3 | – | ||
| Hospitalization due to an HF aggravation | ||||
| HFpEF | ≤ 60 bpm | 41 | Reference | |
| (n = 216, 17.2%person-year) | 61–80 bpm | 118 | 0.70 (0.51–0.97) | 0.030 |
| 81–110 bpm | 51 | 0.58 (0.39–0.85) | 0.005 | |
| >110 bpm | 6 | 0.87 (0.37–2.01) | 0.738 | |
| In HFmrEF: | ≤ 60 bpm | 26 | Reference | |
| (n = 180, 17.5%erson-year) | 61–80 bpm | 73 | 0.83 (0.55–1.27) | 0.398 |
| 81–110 bpm | 55 | 1.09 (0.70–1.70) | 0.696 | |
| >110 bpm | 26 | 1.99 (1.18–3.36) | 0.010 | |
| HFrEF: | ≤ 60 bpm | 17 | Reference | |
| (n = 128, 20.2%/person-year) | 61–80 bpm | 57 | 0.66 (0.40–1.07) | 0.092 |
| 81–110 bpm | 33 | 0.63 (0.36–1.09) | 0.100 | |
| >110 bpm | 21 | 1.06 (0.58–1.94) | 0.855 | |
| Hospitalization due to other causes | ||||
| HFpEF | ≤ 60 bpm | 2 | Reference | |
| (n = 5, 0.4%person-year) | 61–80 bpm | 0 | 0.00 (0.01–4.01) | 0.944 |
| 81–110 bpm | 2 | 0.61 (0.07–5.35) | 0.652 | |
| >110 bpm | 1 | 8.21 (0.47–94.0) | 0.149 | |
| In HFmrEF: | ≤ 60 bpm | 5 | Reference | |
| (n = 17, 1.7%/person-year) | 61–80 bpm | 6 | 0.32 (0.10–0.99) | 0.048 |
| 81–110 bpm | 1 | 0.10 (0.01–0.82) | 0.032 | |
| >110 bpm | 5 | 2.00 (0.61–6.57) | 0.253 | |
| HFrEF | ≤ 60 bpm | 2 | Reference | |
| (n = 17, 2.7%/person-year) | 61–80 bpm | 10 | 0.91 (0.19–4.42) | 0.904 |
| 81–110 bpm | 3 | 0.41 (0.06–2.76) | 0.362 | |
| >110 bpm | 2 | 0.61 (0.08–4.92) | 0.640 | |
A multivariable Cox regression was performed with the variables listed in Table 1.
CI, confidence interval; HF, heart failure; HR, heart rate; HFpEF, heart failure preserved ejection fraction; HR, heart rate; HFrEF, heart failure reduced ejection fraction; bpm, beat per minute.
Bold values mean statistically significant value (p < 0.05).
The penalized spline for the composite primary outcome showed the minimum hazard in the HR 80–110 bpm strata (HR = 88) among HFpEF patients. Similar to the results of our cox regression analysis, the hazard curve in HFmrEF patients gradually increased to the right in the HR >110 bpm strata. In HFrEF patients, the hazard curve did not show any significant increase or decrease depending on the HR (Figure 4). The penalized spline for parity resulted in a U-shaped hazard curve with the minimum hazard (i.e., composite primary endpoint—all-cause mortality and all-cause hospitalization) in the group with HR = 88 bpm (Figure 5).
Figure 4.
Cox regression analysis – penalized spline. The primary endpoint according to heart failure in patients with HFpEF, HFmrEF, and HFrEF is shown. (A) Penalized spline regression in HFpEF, (B) Penalized spline regression in HFmrEF, and (C) Penalized spline regression in HFrEF. HFpEF, heart failure with preserved ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFrEF, heart failure with reduced ejection fraction.
Figure 5.
Cox regression analysis—penalized spline. The primary endpoint according to heart failure in patients with HFpEF (reference heart rate of 88 bpm) is shown. HFpEF, heart failure with preserved ejection fraction.
Considering gender, age, diastolic blood pressure, and ICD as correction variables, the difference in the influence on primary outcomes between HF groups (HFpEF vs. HFmrEF vs. HFrEF) according to the HR strata was not statistically significant (p = 0.7827). Also, the difference in the influence on primary outcomes between AF types according to the HR strata was not statistically significant (p =0.395).
Secondary Outcomes Related to the HR
In the HFpEF group, the secondary outcome rate was significantly lower than that in the other two groups. However, the secondary outcome did not differ significantly according to HR strata within each HF group. The cumulative incidences of the components of the secondary outcome are shown in Table 3.
Table 3.
Cox regression analyses of the effect of the heart rate on the secondary endpoint.
| HR strata, beats per min | No. of events | Hazard ratio | P value | |
|---|---|---|---|---|
| (% per person-year) | (95% CI) | |||
| Composite secondary endpoint | ||||
| In HFpEF | ≤ 60 bpm | 2 | Reference | |
| (n = 17, 1.3%/person-year) | 61–80 bpm | 8 | 0.64 (0.13–3.25) | 0.591 |
| 81–110 bpm | 6 | 1.44 (0.28–7.58) | 0.664 | |
| >110 bpm | 1 | 4.88 (0.37–64.75) | 0.230 | |
| In HmFrEF: | ≤ 60 bpm | 8 | Reference | |
| (n = 45, 4.4%/person-year) | 61–80 bpm | 21 | 0.50 (0.21–1.22) | 0.127 |
| 81–110 bpm | 8 | 0.44 (0.16–1.19) | 0.105 | |
| >110 bpm | 8 | 2.78 (0.87–8.90) | 0.086 | |
| In HFrEF: | ≤ 60 bpm | 2 | Reference | |
| (n = 28, 4.4%/person-year) | 61–80 bpm | 18 | 1.75 (0.41–7.59) | 0.453 |
| 81–110 bpm | 6 | 0.91 (0.18–4.64) | 0.909 | |
| >110 bpm | 2 | 0.55 (0.07–4.22) | 0.561 | |
A multivariable Cox regression was performed with the variables listed in Table 1 without echoparameters.
CI, confidence interval; HF, heart failure; HR, heart rate; HFpEF, heart failure preserved ejection fraction; HR, heart rate; HFrEF, heart failure reduced ejection fraction; bpm, beat per minute.
Discussion
In this study, we observed a U-shaped association between the resting HR and cardiovascular outcomes in patients with HFpEF and AF, with the lowest event rates observed in patients with HR 81–110 bpm. However, the cardiovascular outcome rate was similar among HFmrEF patients with HR ≤ 110 bpm, and the rate increased only in patients with a higher resting HR (HR >110 bpm). The optimal HR in HF in patients with AF has been studied previously. Post-hoc analysis of the RACE II study showed that a lenient HR was non-inferior in patients with HF and AF compared to a strict HR control. The average EF in that study was approximately 47–48% (13), which is comparable to the 45% observed in the HFmrEF group in our study. In the HFmrEF group in our study, there was no difference in the cardiovascular outcomes in patients with HR ≤ 110 bpm, which is similar to the result of the previous study. Similarly in the HFrEF group, there was no statistical significance, but the tendency of HR to increase as the resting heart rate increased was shown. The tendency of HFrEF group shows similar conclusion to previous study; rate control using b-blockers should not be used preferentially to improve prognosis in patients with concomitant heart failure and atrial fibrillation (14). Actually, EF in the previous study group is similar to EF in this HFrEF group (average EF; 23 vs. 31%). The previous study did not analyze HFpEF patients alone, whereas in our study, we classified and analyzed HFpEF patients separately. We found a U shape association of the resting HR to the cardiovascular outcomes in HFpEF patients with AF, indicating increased adverse cardiovascular outcomes with low or high HRs.
AF is commonly observed in HF irrespective of the concomitant LVEF (1). The prevalence of HF is increasing, and older age, non-cardiac comorbidities, higher rates of AF, and limited treatment options further complicate the management of HF cases. Since these patients are often elderly and highly symptomatic and often have a poor quality of life (15), it is important to alleviate symptoms, improve wellbeing, and reduce hospitalization (16). There is no consensus on treatments that can effectively improve the clinical outcomes in HFpEF patients. However, HFrEF is more commonly associated with coronary artery disease and can be treated with evidence-based therapies. A previous study suggested that a lower resting HR is associated with better survival in HFrEF patients with sinus rhythm but not in those with AF (6). HFpEF and AF are common coexistent conditions that have a substantial impact on the patients' wellbeing. The prevalence of HFpEF in four major AF trials (17) has been 8–24%. The difference in the HF incidence in each trial may be due to the different AF types included in each trial. In addition, the prevalence of AF in HFpEF varied among seven large HF trials, ranging from 21 to 33% (17). AF is a strong and independent prognostic factor in HF patients and has been shown in clinical trials and observational studies to increase the risk of death (14, 18). Both HFpEF and AF share similar clinical aspects and are associated with aging, hypertension, and diastolic dysfunction. Thus, they affect each other's adverse cardiovascular outcomes (19). Some guidelines have suggested that the optimal resting HR in HF patients may be 60–110 bpm (20–23). Strict HR control is associated with a worse outcome (24). Patients with HF and AF exhibit structural changes that cause AF (e.g., an enlarged left atrium (LA), LA to LV flow during early diastolic phase, and loss of A waves), making it more difficult to determine the appropriate HR because of the relationship between these two vicious twins (17, 25, 26).
A previous study in AF patients showed that a lenient rate control is as effective as a strict rate control in terms of major clinical events (6). The patients included in the study showed a preserved EF of about 52% in both the lenient control and strict control groups, with about 15% of the patients having an EF under 40%. In a post-hoc analysis, in about 32% patients with reduced EF, the overall average EF was 47–48%, mostly referred to as HFpEF. However, this association of HF with AF was observed when there was no strict classification for HFpEF and HFrEF.
A low HR is beneficial for both patients with HF (27, 28) and those with coronary artery disease (29). However, this presumption is primarily derived from studies in patients with sinus rhythm. A major difference in the evaluation of the diastolic function between patients with AF and those with sinus rhythm is the elimination of A waves seen in the late diastolic phase, i.e., “loss of A waves”. In patients with sinus rhythm with a relaxation abnormality, an increase in diastolic phase due to reduced HR will assist in LV filling, thereby maintaining the cardiac output, increasing the coronary blood supply, and alleviating the symptoms. However, in cases of severe diastolic dysfunction, an increase in the diastolic phase due to reduced HR will not significantly improve the cardiac output because LV filling is dependent on only the HR (especially for restrictive patterns). In AF patients, LV filling is largely dependent on the E wave acceleration time and LV diastolic function, since there are no A waves. Therefore, if the rate is adjusted strictly in patients with diastolic dysfunction AF, the filling from LA to LV is reduced, and the flexibility of the LA is reduced due to AF, thus increasing the pulmonary congestion. This worsens the symptoms and deteriorates the general condition, which marks the beginning of a vicious cycle that causes uncontrolled AF. This hypothesis is consistent with the notion that beta-blockers do not improve the prognosis in patients with HF and AF (30, 31).
Our study has several limitations. First, the diagnosis of HF may have been affected by the variability among clinicians since HF is a clinical syndrome and the diagnosis is mainly based on the presence of typical symptoms and signs rather than specific test results (2). Sometimes, it can be difficult to distinguish which symptoms are caused by heart failure or arrhythmia, as determined by clinicians. This could explain why the heart failure rate is lower in our cohort compared to other studies (13, 32–34). Second, although the HR is clinically determined to be in the resting state during hospitalization in the outpatient clinic, this is only a single measure, and we could not obtain information on the HR variability. Third, as this study was conducted with a relatively short follow-up period (median 2.2 years), the number of adverse events cases is small. Also, follow-up echocardiographic data are not available. So the proportion of patients with reversible LV dysfunction in the HFrEF group could not be determined. This could have resulted in the lower than predicted adverse outcome rates about death especially in the HFrEF group. Finally, this study was conducted in a single country; therefore, the application of our results to other regions requires more study.
Conclusion
In patients with HF and AF, a high HR (>110 bpm) is associated with an increased risk of cardiac adverse events compared with an HR ≤ 110 bpm regardless of the type of HF. Importantly, a very low HR (≤ 60 bpm) in patients with HFpEF and AF is also associated with an increased risk of U-shaped cardiac adverse events.
Data Availability Statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF] registry.
Ethics Statement
The studies involving human participants were reviewed and approved by Research Ethics Committee of all 12 tertiary centers including Ewha Womans University Mokdong Hospital (No. 216-02-056). The patients/participants provided their written informed consent to participate in this study.
Author Contributions
SS and JP contributed to conception and design of the study. J-SK, E-KC, M-JC, T-HK, J-KP, J-ML, K-WK, J-SU, JK, CK, J-BK, HP, and BJ organized the database. HL performed the statistical analysis. SS wrote the first draft of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.
Funding
This study was supported by a research grant from the Korean Healthcare Technology R&D project funded by the Ministry of Health and Welfare (HI15C1200, HC19C0130). This research was also supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2017R1E1A1A01078382).
Conflict of Interest
BJ has served as a speaker for Bayer, BMS/Pfizer, Medtronic, and Daiichi-Sankyo and has received research funds from Medtronic and Abbott. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.787869/full#supplementary-material
References
- 1.Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. (2016) 37:2893–962. 10.1093/eurheartj/ehw210 [DOI] [PubMed] [Google Scholar]
- 2.Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. (2018) 378:417–27. 10.1056/NEJMoa1707855 [DOI] [PubMed] [Google Scholar]
- 3.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. (2016) 69:1167. 10.1002/ejhf.592 [DOI] [PubMed] [Google Scholar]
- 4.Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JGP, Alings AM et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. (2010) 362:1363–73. 10.1056/NEJMoa1001337 [DOI] [PubMed] [Google Scholar]
- 5.Writing C, Maddox TM, Januzzi JL, Jr., Allen LA, Breathett K, Butler J, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. (2021) 77:772–810. 10.1016/j.jacc.2020.11.022 [DOI] [PubMed] [Google Scholar]
- 6.Cullington D, Goode KM, Zhang J, Cleland JG, Clark A L. Is heart rate important for patients with heart failure in atrial fibrillation? JACC Heart Fail. (2014) 2:213–20. 10.1016/j.jchf.2014.01.005 [DOI] [PubMed] [Google Scholar]
- 7.Daoud EG, Weiss R, Bahu M, Knight BP, Bogun F, Goyal R. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol. (1996) 78:1433–6. 10.1016/s0002-9149(97)89297-1 [DOI] [PubMed] [Google Scholar]
- 8.Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. (1997) 30:1039–45. 10.1016/s0735-1097(97)00254-4 [DOI] [PubMed] [Google Scholar]
- 9.Clyde WY, Mariell J, Biykem B, Javed B, Donald EC Jr, Mark HD et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. (2013) 128:e240–327. 10.1016/j.jacc.2013.05.019 [DOI] [PubMed] [Google Scholar]
- 10.Lim C, Kim TH, Yu HT, Lee SR, Cha MJ, Lee JM et al. Effect of alcohol consumption on the risk of adverse events in atrial fibrillation: From the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) registry. Europace. (2021) 23:548–56. 10.1093/europace/euaa340 [DOI] [PubMed] [Google Scholar]
- 11.Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, et al. Developing therapies for heart failure with preserved ejection fraction: Current state and future directions. JACC Heart failure. (2014) 2:97–112. 10.1016/j.jchf.2013.10.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Meira-Machado L, Cadarso-Suarez C, Gude F, Araujo A. Smoothhr: An r package for pointwise nonparametric estimation of hazard ratio curves of continuous predictors. Comput Math Methods Med. (2013) 2013:745742. 10.1155/2013/745742 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JGP, Hillege HL, Alings M et al. Lenient vs. Strict rate control in patients with atrial fibrillation and heart failure: A post-hoc analysis of the RACE II study. Eur J Heart Fail. (2013) 15:1311–8. 10.1093/eurjhf/hft093 [DOI] [PubMed] [Google Scholar]
- 14.Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. Beta-blockers in heart failure collaborative G. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: An individual-patient data meta-analysis. Lancet. (2014) 384:2235–43. 10.1016/S0140-6736(14)61373-8 [DOI] [PubMed] [Google Scholar]
- 15.Fukuta H, Goto T, Wakami K, Ohte N. Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. Eur J Prev Cardiol. (2016) 23:78–85. 10.1177/2047487314564729 [DOI] [PubMed] [Google Scholar]
- 16.Lewis EF, Lamas GA, O'Meara E, Granger CB, Dunlap ME, McKelvie RS, et al. Investigators C. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. (2007) 9:83–91. 10.1016/j.ejheart.2006.10.012 [DOI] [PubMed] [Google Scholar]
- 17.Kotecha D, Lam CS, Van Veldhuisen DJ, Van Gelder IC, Voors AA, Rienstra M. Heart failure with preserved ejection fraction and atrial fibrillation: Vicious twins. J Am Coll Cardiol. (2016) 68:2217–28. 10.1016/j.jacc.2016.08.048 [DOI] [PubMed] [Google Scholar]
- 18.Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L, et al. meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. (2009) 11:676–83. 10.1093/eurjhf/hfp085 [DOI] [PubMed] [Google Scholar]
- 19.Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL, et al. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: A community-based study from the Netherlands. J Am Coll Cardiol. (2015) 66:1000–7. 10.1016/j.jacc.2015.06.1314 [DOI] [PubMed] [Google Scholar]
- 20.Li SJ, Sartipy U, Lund LH, Dahlström U, Adiels M, Petzold M, et al. Prognostic significance of resting heart rate and use of beta-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: Findings from the Swedish heart failure registry. Circ Heart Fail. (2015) 8:871–9. 10.1161/CIRCHEARTFAILURE.115.002285 [DOI] [PubMed] [Google Scholar]
- 21.Hagens VE, Crijns HJ, Van Veldhuisen DJ, Van Den Berg MP, Rienstra M, Ranchor AV, et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the rate control versus electrical cardioversion (RACE) study. Am Heart J. (2005) 149:1106–11. 10.1016/j.ahj.2004.11.030 [DOI] [PubMed] [Google Scholar]
- 22.Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. (2002) 347:1834–40. 10.1056/NEJMoa021375 [DOI] [PubMed] [Google Scholar]
- 23.Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagen VE, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace. (2006) 8:935–42. 10.1093/europace/eul106 [DOI] [PubMed] [Google Scholar]
- 24.Mareev Y, Cleland JG. Should beta-blockers be used in patients with heart failure and atrial fibrillation? Clin Ther. (2015) 37:2215–24. 10.1016/j.clinthera.2015.08.017 [DOI] [PubMed] [Google Scholar]
- 25.Rosenberg MA, Manning WJ. Diastolic dysfunction and risk of atrial fibrillation: A mechanistic appraisal. Circulation. (2012) 126:2353–62. 10.1161/CIRCULATIONAHA.112.113233 [DOI] [PubMed] [Google Scholar]
- 26.Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. (2018) 39:4277–84. 10.1093/eurheartj/ehy626 [DOI] [PubMed] [Google Scholar]
- 27.Neuberger HR, Mewis C, Veldhuisen DJ, Schotten U, Gelder IC, Allessie MA, et al. Management of atrial fibrillation in patients with heart failure. Eur Heart J. (2007) 28:2568–77. 10.1093/eurheartj/ehm341 [DOI] [PubMed] [Google Scholar]
- 28.Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. (2010) 376:886–94. 10.1016/S0140-6736(10)61259-7 [DOI] [PubMed] [Google Scholar]
- 29.Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. (2005) 352:1951–8. 10.1056/NEJM200508183530717 [DOI] [PubMed] [Google Scholar]
- 30.Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. (2001) 103:1428–33. 10.1161/01.cir.103.10.1428 [DOI] [PubMed] [Google Scholar]
- 31.Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF study. Eur J Heart Fail. (2006) 8:539–46. 10.1016/j.ejheart.2006.01.015 [DOI] [PubMed] [Google Scholar]
- 32.Silva-Cardoso J, Zharinov OJ, Ponikowski P, Naditch-Brûlé L, Lewalter T, Brette S et al. Heart failure in patients with atrial fibrillation is associated with a high symptom and hospitalization burden: the RealiseAF survey. Clin Cardiol. (2013) 36:766–74. 10.1002/clc.22209 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA et al. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. Eur J Heart Fail. (2015) 17:570–82. 10.1002/ejhf.254 [DOI] [PubMed] [Google Scholar]
- 34.Badheka AO, Rathod A, Kizilbash MA, Bhardwaj A, Ali O, Afonso L et al. Comparison of mortality and morbidity in patients with atrial fibrillation and heart failure with preserved versus decreased left ventricular ejection fraction. Am J Cardiol. (2011) 108:1283–8. 10.1016/j.amjcard.2011.06.045 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF] registry.